<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Endnu en tilføjelse til kalenderen:]]></title><description><![CDATA[<p dir="auto">Endnu en tilføjelse til kalenderen:<br />
Zanolimumab (HuMax CD4) i Mycosis Fungoides (CTCL) fase III:</p>
<p dir="auto">Estimated Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)</p>
<p dir="auto">Det har vel også lidt indflydelse på Genmab, hvis der kommer positive resultater fra TenX Biopharma.</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/448288/endnu-en-tilfjelse-til-kalenderen</link><generator>RSS for Node</generator><lastBuildDate>Sun, 21 Jun 2026 11:37:33 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/448288.rss" rel="self" type="application/rss+xml"/><pubDate>Mon, 13 Dec 2010 11:57:06 GMT</pubDate><ttl>60</ttl></channel></rss>